Skip to main content
SpringerLink
Log in

Farmaci interferenti sulla steroidogenesi cortico-surrenalica

  • Commissione Farmaci della S.I.E.
  • Interferenze farmacologiche sulla diagnostica ormonale dell’asse ipotalamo-ipofisi-surrene (HPA)
  • Published:
L’Endocrinologo Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Bibliografia

  1. Nieman LK. Medical therapy of Cushing’s disease. Pituitary 5: 77, 2002.

    Article  CAS  PubMed  Google Scholar 

  2. Broadley AJ, Korszun A, Abdelaal E, Moskvina V, Jones CJ, Nash GB, Ray C, Deanfield J, Frenneaux MP. Inhibition of cortisol production with metyrapone prevents mental stress-induced endothelial dysfunction and baroreflex impairment. J Am Coll Cardiol 46: 344, 2005.

    Article  CAS  PubMed  Google Scholar 

  3. Winhusen T, Somoza E, Harrer JM, Moore E, Ussery T, Kropp F, Singal B, Elkashef A, Mojsiak J. Metyrapone and cocaine: a double-blind, placebo-controlled drug interaction study. Pharmacol Biochem Behav 80: 631, 2005.

    Article  CAS  PubMed  Google Scholar 

  4. Deuschle M, Lecei O, Stalla GK, Landgraf R, Hamann B, Lederbogen F, Uhr M, Luppa P, Maras A, Colla M, Heuser I. Steroid synthesis inhibition with ketoconazole and its effect upon the regulation of the hypothalamus-pituitary-adrenal system in healthy humans. Neuropsychopharmacology 28: 379, 2003.

    Article  CAS  PubMed  Google Scholar 

  5. Scholz M, Jennrich R, Strum S, Brosman S, Johnson H, Lam R. Long-term outcome for men with androgen independent prostate cancer treated with ketoconazole and hydrocortisone. J Urol 173: 1947, 2005.

    Article  CAS  PubMed  Google Scholar 

  6. Albert SG, DeLeon MJ, Silverberg AB. Possible association between high-dose fluconazole and adrenal insufficiency in critically ill patients. Crit Care Med 29: 668, 2001.

    Article  CAS  PubMed  Google Scholar 

  7. Magill SS, Puthanakit T, Swoboda SM, Carson KA, Salvatori R, Lipsett PA, Hendrix CW. Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients. Antimicrob Agents Chemother 48: 2471, 2004.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Michaud LB, Buzdar AU. Risks and benefits of aromatase inhibitors in post-menopausal breast cancer. Drug Saf 21: 297, 1999.

    Article  CAS  PubMed  Google Scholar 

  9. Beardwell CG, Hindley AC, Wilkinson PM, St John J, Bu’lock D. Hormonal changes in postmenopausal women with breast cancer treated with trilostane and dexamethasone. Clin Endocrinol (Oxf) 23: 413, 1985.

    Article  CAS  Google Scholar 

  10. le Roux PA, Tregoning SK, Zinn PM, van der Spuy ZM. Inhibition of progesterone secretion with trilostane for mid-trimester termination of pregnancy: randomized controlled trials. Hum Reprod 17: 1483, 2002.

    Article  PubMed  Google Scholar 

  11. Klausen NO, Moelgaard J, Ferguson AH, Jensen JK, Larsen C, Paaby P. Negative Synacthen test during etomidate infusion. Lancet 8354: 848, 1983.

    Article  Google Scholar 

  12. Malerba G, Romano-Girard F, Cravoisy A, Dousset B, Nace L, Levy B, Bollaert PE. Risk factors of relative adrenocortical deficiency in intensive care patients needing mechanical ventilation. Intensive Care Med 31: 388, 2005.

    Article  PubMed  Google Scholar 

  13. Schenarts CL, Burton JH, Riker RR. Adrenocortical dysfunction following etomidate induction in emergency department patients. Acad Emerg Med 8: 1, 2001.

    Article  CAS  PubMed  Google Scholar 

  14. Terzolo M, Pia A, Berruti A, Osella G, Ali A, Carbone V, Testa E, Dogliotti L, Angeli A. Low-dose monitored mitomane treatment achieves the therapeutic range with manageable side effects in patients with adrenocortical cancer. J Clin Endocrinol Metab 85: 2234, 2000.

    CAS  PubMed  Google Scholar 

  15. Kasperlik-Zaluska AA. Clinical results of the use of mitotane for adrenocortical carcinoma. Braz J Med Biol Res 33: 1191, 2000.

    Article  CAS  PubMed  Google Scholar 

  16. Robinson BG, Hales IB, Henniker AJ, Ho K, Luttrell BM, Smee IR, Stiel JN. The effect of o,p.’-DDD on adrenal steroid replacement therapy requirements. Clin Endocrinol 27: 437, 1987.

    Article  CAS  Google Scholar 

  17. Dobs AS, Schrott H, Davidson MH, Bays H, Stein EA, Kush D, Wu M, Mitchel Y, Illingworth RD. Effects of high-dose simvastatin on adrenal and gonadal steroidogenesis in men with hypercholesterolemia. Metabolism 49: 1234, 2000.

    Article  CAS  PubMed  Google Scholar 

  18. Dobs AS, Sarma PS, Schteingart D. Long-term endocrine function in hypercholesterolemic patients treated with pravastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Metabolism 42: 1146, 1993.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinica Medica, Ospedale San Luigi, Regione Gonzole 10, 10043, Orbassano (TO), Italia

    Massimo Terzolo

  2. Dipartimento di Scienze Cliniche e Biologiche, Medicina Interna I, Ospedale San Luigi, Regione Gonzole 10, 10043, Orbassano (TO), Italia

    Giuseppe Reimondo

Authors
  1. Massimo Terzolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Reimondo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Massimo Terzolo.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Terzolo, M., Reimondo, G. Farmaci interferenti sulla steroidogenesi cortico-surrenalica. L’Endocrinologo 9, 82–85 (2008). https://doi.org/10.1007/BF03344613

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03344613

Search

Navigation